A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects

Exclusion criteria

• . Medical history of cardiovascular and respiratory system (such as sleep apnea syndrome, pulmonary heart disease or chronic bronchial asthma), liver, kidney, nervous system (such as epilepsy), blood system or mental disorders that the researcher considers clinically significant;
• . Medical history of cardiovascular system disease, including but not limited to history or family history of syncope, coronary heart disease (such as coronary angiography diagnosis of coronary heart disease, history of acute coronary syndrome, history of myocardial infarction, etc.), valvular heart disease, heart failure, history of non-drug-induced bradyarrhythmia, frequent ventricular premature beats, ventricular tachycardia, etc.; or previous QTc prolongation or other risk factors for torsades de pointes (hypokalemia, etc.), or a family history of a first-degree relative (i.e., biological parent, brother, sister or child) with short QT syndrome, long QT syndrome, sudden death of unknown cause in his youth (less than/equal to 40 years old), drowning or sudden infant death syndrome;
• . Medical history of symptomatic head trauma;
• . History of frequent nausea or vomiting of any etiology;
• . Medical history of glaucoma or any condition affecting pupil size;
• . Major surgery or major trauma within 6 months prior to screening or planning to undergo surgery during the study;
• . Known to be allergic to two or more kinds of food and drugs;
• . Known to be allergic to opioids, or have contraindications for the use of such drugs;

AUC0-t

Timeframe: Pre-dose to 72 hours post-dose